TLX Telix Pharmaceuticals

Edison Investment Research Limited: Edison issues outlook on Telix Pharmaceuticals (TLX)

Edison Investment Research Limited
Edison Investment Research Limited: Edison issues outlook on Telix Pharmaceuticals (TLX)

02-Jul-2020 / 15:49 GMT/BST

 

London, UK, 2 July 2020

Edison issues outlook on Telix Pharmaceuticals (TLX)

We expect 2020 to be a major turning point for Telix Pharmaceuticals. The regulatory submissions for illumet will determine whether the company will start commercial operations in 2021. The clinical groundwork for TLX-250-CDx is being laid in the ongoing pivotal Phase III ZIRCON study, which recently restarted in Europe and is expected to be fully enrolled by the end of 2020. Finally, the company has guided towards starting new clinical studies for TLX591 and TLX250 in late 2020, contingent on FDA feedback and financing. This report provides our clinical and commercial outlook.

 

We increased our valuation to A$571m or A$2.25 per basic share, from A$522m or A$2.06 per basic share. This increase is due to us updating the epidemiological numbers in our model to reflect the latest projections from the WHO and NIH on renal and prostate cancers, and because we now include Breakthrough designation for TLX250-CDx. Otherwise our forecasts remain unchanged.


to view the full report.

 

to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the .

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway,

 

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1085021  02-Jul-2020 

fncls.ssp?fn=show_t_gif&application_id=1085021&application_name=news&site_id=research_pool
EN
02/07/2020

Underlying

TLXTelix Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Telix Pharmaceuticals

 PRESS RELEASE
Free
TLX Telix Pharmaceu...

Telix Appoints David Gill as Non-Executive Director

Telix Appoints David Gill as Non-Executive Director MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and...

April 1, 2026 1 EN
 PRESS RELEASE
Free
TLX Telix Pharmaceu...

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer...

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients....

March 15, 2026 1 EN
 PRESS RELEASE
Free
TLX Telix Pharmaceu...

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following link: MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) – has achieved its primary objectives, ...

March 9, 2026 1 EN
 PRESS RELEASE
Free
TLX Telix Pharmaceu...

Investor Education Webinar

Investor Education Webinar The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate cancer. Speakers: Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Centre (MTIC);P...

March 1, 2026 1 EN
 PRESS RELEASE
Free
TLX Telix Pharmaceu...

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Opti...

Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry1, defining the potential prognostic value of PSMA-PET2 imaging through artificial intelligence (AI). PROMISE (PROstate cancer Molecular Imaging Standardized Evaluation)-PET is a multi-center, prospective, observational, non-in...

February 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch